The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunothera...
Serena Porcari, L. Bolte, J. Björk et al.· Cancer Cell· 0 citations
The gut microbiome has been linked to cancer in many cross-sectional studies. These studies compared individuals with and without cancer, but they do not establish causation. Prospective cohort studies, with faecal samples collected before a cancer diagnosis, will be instrumental in assessing the role of the gut microb...
E. Vogtmann, Caroline Y. Um, S. Zouiouich et al.· The Lancet Microbe· 0 citations
Cancer remains a leading cause of morbidity and mortality worldwide, and the incidence of new cancer cases is rising. While established lifestyle factors such as smoking, obesity, and diet contribute to cancer risk, the gut microbiome has emerged as a hallmark of cancer. However, the role of the gut microbiome in cance...
E. Oosterhout, R. S. Leijdesdorff, O. Kambur et al.· medRxiv· 0 citations
Summary Background Gene-environment interactions (GxE) are fundamental for understanding the mechanisms of human diseases. Tobacco smoking is of particular interest for Inflammatory bowel disease (IBD), as it worsens Crohn’s disease (CD) but protects against ulcerative colitis (UC). Here, we systematically examined the...
Jing-Jing Bai, R. Gacesa, J. Björk et al.· EBioMedicine· 0 citations
It is shown that people who are diagnosed with cancer after microbiome sampling have microbiome alterations like those found in diagnosed cancer cases, albeit to a lower degree, across the four populations studied, indicating that the microbiome may evolve towards the one found in cancer well before cancer is diagnosed...
G. Vitali, J. Bjork, O. Kambur et al.· medRxiv· 0 citations
Results reveal that CD-derived phIFs show marked heterogeneity in basal IL13RA2 expression, which is strongly induced by IL13 and associated with JAK1-STAT6 pathway activation, both of which are effectively suppressed by upadacitinib.
Li Wang, Rui-Bin Wu, S. de Jong et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.